PureTech News

Statement regarding termination of discussions with Nektar Therapeutics (“Nektar”)”

Statement Regarding Recent Press Speculation

PureTech to Present at the Morgan Stanley Global Healthcare Conference

PureTech Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

PureTech Founded Entity Gelesis Presented Clinical Data from the LIGHT-UP Study at the International Congress of Endocrinology that Suggests New Gelesis Oral Hydrogel May Improve Insulin Sensitivity and Favorably Impact Metabolic Syndrome

PureTech Health plc - Half-Year Report

PureTech Founded Entity Akili to List on Nasdaq Following Successful Business Combination with Social Capital Suvretta Holdings Corp. I

PureTech to Receive up to Approximately $115.4 Million from Sale of a Portion of Founded Entity Shares

PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

Notice of Half-Yearly Results